Article Figures & Data
Figures
- Figure 1.
Representative traces of mutation status. A, patient 28 WTBRAF exon 15, codon 600: valine (GTG, arrow). B, patient 27 V600EBRAF exon 15, codon 600, showing a valine → glutamic acid substitution (GTG to GAG, arrow). C, patient 25 WTNRAS exon 2, codon 13 (GGT, arrow). D, patient 20 G13DNRAS exon 2, codon 13 showing a glycine → aspartic acid substitution (GGT to GAT, arrow).
Tables
- Table 1.
BRAF and NRAS mutations in melanoma specimens: relationship with time to progression
Patient no. BRAF NRAS Time to progression while on 17-AAG (mo) 20 WT G13D 49 24 V600E WT 2 25 V600E WT 1.5 26 WT WT 1.5 27 V600E WT 15 28 WT WT 1 NOTE: Six patients with metastatic malignant melanoma were treated with 17-AAG at doses of 320 to 450 mg/m2/wk. The time to progression on treatment along with BRAF and NRAS mutation status are summarized.
April 2008
Volume 7, Issue 4
Volume 7, Issue 4
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Jump to section
Advertisement